Zymeworks Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Zymeworks has been growing earnings at an average annual rate of 21.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 37.8% per year.

Anahtar bilgiler

21.8%

Kazanç büyüme oranı

28.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı37.8%
Özkaynak getirisi-31.0%
Net Marj-182.8%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Gelir ve Gider Dağılımı

Zymeworks nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:ZYME Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2462-114600
30 Jun 2463-113630
31 Mar 2450-126690
31 Dec 2376-119700
30 Sep 23462205870
30 Jun 23448186860
31 Mar 23446173800
31 Dec 22412124750
30 Sep 2230-224490
30 Jun 2232-237490
31 Mar 2228-240530
31 Dec 2127-212420
30 Sep 2122-211500
30 Jun 2121-223560
31 Mar 2131-194490
31 Dec 2039-181550
30 Sep 2025-215720
30 Jun 2030-173630
31 Mar 2026-163620
31 Dec 1930-145630
30 Sep 1957-64400
30 Jun 1951-52360
31 Mar 1965-29310
31 Dec 1853-37300
30 Sep 1874-13280
30 Jun 1872-11260
31 Mar 1852-16190
31 Dec 1752-11180
30 Sep 174-55190
30 Jun 176-51160
31 Mar 1711-47170
31 Dec 1611-34130
30 Sep 1610-3090
31 Dec 1510-1950
31 Dec 142-1340

Kaliteli Kazançlar: ZYME is currently unprofitable.

Büyüyen Kar Marjı: ZYME is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ZYME is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.

Büyüme Hızlandırma: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: ZYME has a negative Return on Equity (-30.97%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin